Baxter to sell its kidney-care business in a $3.8 billion deal to Carlyle Group
Shares of Baxter International Inc. gained ground early Tuesday, after the healthcare-products company announced an agreement to sell its kidney-care business — to be named Vantive — to private-equity investor Carlyle Group Inc. in a deal valued at $3.8 billion.
